Clinical trials: Plasma Cell Myeloma, open to volunteers
Myeloma
REal World MAIA UK OutcomEs
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated…
- Trial name
- REMAKE (NCT07532473)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Plasma Cell Myeloma
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma.
- Trial name
- NCT05208307
- Testing
- Belantamab Mafodotin, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Emory University
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Plasma Cell Neoplasms
Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma
A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple…
- Trial name
- MAIELLA (NCT07777406)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma
Delayed Toxicities Post-CAR-T
This is an observational umbrella protocol evaluating toxicities after CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) for RRMM, with a goal to identify key inflammatory features contributing to toxicities, define…
- Trial name
- NCT07665307
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
- Conditions
- B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma
- Trial name
- NCT05092451
- Testing
- Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Other Plasma Cell Neoplasms
Longitudinal Data Registry of Plasma Cell Dyscrasia
The goal of this multicenter observational study is to better understand the clinical and molecular characteristics, disease progression, treatment response, and clinical outcomes of patients with plasma cell dyscrasias…
- Trial name
- NCT06760052
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloma Multiple, Plasma Cell Leukemia
The Norwegian Immunotherapy in Multiple Myeloma Study
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway.
- Conditions
- Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
- Trial name
- NIMMS (NCT06855121)
- Testing
- Teclistamab, Elranatamab, Ciltacabtagene Autoleucel
- Where
- 23 sites in Norway
- Volunteers
- 400 people
- Sponsor
- St. Olavs Hospital
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others.
- Trial name
- iFIT (NCT07649525)
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,226 people
- Sponsor
- University of Leeds
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy
Pre-malignant States to Hematologic Malignancies in Firefighters
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic…
- Conditions
- Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia
- Trial name
- NCT06870760
- Testing
- Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms
68Ga-BCMA PET/CT in Multiple Myeloma
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple…
- Conditions
- Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT07319897
- Testing
- 68Ga-BCMA PET/CT
- Where
- 5 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers